Research articleIn vitro protein-binding characteristics of atevirdine (cas 136816-75-6) and its N-dealkylated metabolite
-
Add time:09/05/2019 Source:sciencedirect.com
The in vitro protein-binding characteristics of atevirdine (cas 136816-75-6) (ATV), a non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, and its N-dealkylated metabolite (N-ATV) were studied using equilibrium dialysis. ATV and N-ATV were studied at concentrations of 5, 10, 20, and 30 μM in five protein-containing solutions [albumin 4%, plasma, serum, immune globulin (IgG) 1.5%, α1-acid glycoprotein (AAG)] for 5 h at 37°C. All samples were analyzed by high-performance liquid chromatography. The free fraction of atevirdine in plasma, albumin, and serum was 0.01-0.02 over the range of drug concentrations studied. The fraction unbound (fu) in these protein solutions statistically differed from IgG and AAG (P < 0.05), where the fraction unbound averaged 0.96 and 0.53, respectively. N-ATV had a similar binding profile as ATV with a fraction unbound of 0.04, 0.03, 0.03 in albumin, plasma and serum, respectively. A difference existed in N-ATV binding when compared to IgG and AAG with an average fu of 0.87 and 0.59 (P < 0.05 vs. plasma). The potential clinical implications of the high degree of protein binding for ATV and N-ATV are discussed.
We also recommend Trading Suppliers and Manufacturers of atevirdine (cas 136816-75-6). Pls Click Website Link as below: cas 136816-75-6 suppliers
Prev:Design, synthesis, and biological evaluation of N-acetyl-2-(or 3-)carboxymethylbenzenesulfonamides as cyclooxygenase isozyme inhibitors
Next:Sensitive reversed-phase high-performance liquid chromatographic method for the determination of atevirdine (cas 136816-75-6) and its N-desethyl metabolite in human saliva or cerebrospinal fluid using solid-phase extraction) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Design and synthesis of a conformationally constrained analog of the bis(heteroaryl)piperazine (BHAP) HIV-1 reverse transcriptase inhibitor atevirdine (cas 136816-75-6)09/08/2019
- Concentration-targeted phase I trials of atevirdine (cas 136816-75-6) mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies09/07/2019
- Sensitive reversed-phase high-performance liquid chromatographic method for the determination of atevirdine (cas 136816-75-6) and its N-desethyl metabolite in human saliva or cerebrospinal fluid using solid-phase extraction09/06/2019